Erythropoietin as candidate for supportive treatment of severe COVID-19 - Ehrenreich, Hannelore; Weissenborn, Karin; Begemann, Martin; Busch, Markus; Vieta, Eduard; Miskowiak, Kamilla W. (Molecular medicine (Cambridge, Mass.), 2020)
Keywords: Anemia; Betacoronavirus - pathogenicity; Brain Stem - drug effects; Brain Stem - immunology; Brain Stem - virology; Clinical trials; Coronavirus Infections - drug therapy; Coronavirus Infections - immunology; Coronavirus Infections - pathology; Coronavirus Infections - virology; Coronaviruses; COVID-19; Cytokine Release Syndrome - immunology; Cytokine Release Syndrome - pathology; Cytokine Release Syndrome - prevention & control; Cytokine Release Syndrome - virology; Cytokine storm; Disease; Double-Blind Method; EPO; Erythropoietin - therapeutic use; Homeostasis; Humans; Hypoxia; Inflammation; Intensive care; Lung - drug effects; Lung - immunology; Lung - virology; neuroprotection; Neuroprotective Agents - therapeutic use; Pandemics; Phrenic Nerve - drug effects; Phrenic Nerve - immunology; Phrenic Nerve - virology; Pneumonia; Pneumonia, Viral - drug therapy; Pneumonia, Viral - immunology; Pneumonia, Viral - pathology; Pneumonia, Viral - virology; Proof of Concept Study; Randomized Controlled Trials as Topic; Recombinant Proteins - therapeutic use; Respiration; Respiratory distress syndrome; respiratory function; Respiratory Muscles - drug effects; Respiratory Muscles - immunology; Respiratory Muscles - virology; Respiratory System Agents - therapeutic use; Review; SARS-CoV-2; SARS-CoV-2; recombinant human erythropoietin; Sepsis; Severe acute respiratory syndrome coronavirus 2; Severity of Illness Index; Spinal Cord - drug effects; Spinal Cord - immunology; Spinal Cord - virology; Ventilators; cytokine storm; EPO; SARS-CoV-2; recombinant human erythropoietin; inflammation; neuroprotection; clinical trial design; respiratory function